Dr. Mark Duncan
Tissue Engineering Laboratory Manager
Mark Duncan completed his BS from UCLA in 2008 and subsequently his PhD from Northwestern University in 2015, both in chemical engineering. His graduate work focused on developing ex vivo processes for generating cell therapies from hematopoietic stem cells (HSC).
Afterwards, he spent 9 years in in vitro diagnostics (IVD) at startup company Cue Health, leading a R&D chemistry team and later a process development team tasked with a ~100x scale-up and transfer to manufacturing. Highlights from his tenure at Cue include: co-development of a patented bioconjugation and biosensor combination which formed the heart of the Cue diagnostic platform, working with partner Johnson and Johnson on development of an HIV diagnostic product, establishing and growing a Bioinformatics team, and supporting multiple successful FDA authorizations, including the first ever de novo authorization for an at-home COVID-19 test.
Mark joined the Bhargava group in December 2024, where he brings cell, chemistry, and bioprocess expertise to the MASCOT (Manufacturing Agile and Scalable Tumor Models) project.